Siegfried Grafton is an API manufacturer based in United States. It holds 9 active US drug master files and 3 valid CEPs across a filed portfolio of 9 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 August 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Grafton, United States | Not on file |
| Grafton, United States | 3001655239 |
| Molecule | Regulators | Docs |
|---|---|---|
| Fentanyl | EDQM, US FDA | 3 |
| Brimonidine | EDQM, US FDA | 2 |
| Benzatropine | US FDA | 1 |
| Flavin Mononucleotide | US FDA | 1 |
| Fluoxymesterone | US FDA | 1 |
| Methylnaltrexone | US FDA | 1 |
| Nepafenac | US FDA | 1 |
| Oxandrolone | US FDA | 1 |
| Travoprost | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Siegfried Grafton comes back tiered against every other supplier able to file there.
Start for free